CEO @Arch4BEE | Forward thinking technologist 🚀 #BioTech #LifeSciences #Digitization
Europe
Joined December 2012
- Tweets1.8K
- Following177
- Followers273
- Likes340
A quiet margin killer in pharma manufacturing: the batch is finished, tested, good, and still can't ship because someone has to review the record page by page. 📄
Paper taxes you twice, on speed and on quality. Electronic batch records flip it to review by exception. How long does QP release take on your line?
The Enabling eBR blueprint, live eBR in weeks not years: a4bee.com/article/the-integr…
150 pages to 3. 📄
Review-by-exception collapses a batch record review into a short exception report and cuts review time 50-80%.
It does not skip review. It points your experts at the anomalies, so release becomes a confirmation, not an investigation. ROI usually lands in 12-18 months.
Where review-by-exception sits on the eBR maturity curve: portal.a4bee.com/a/ebr-matur…
If your batch review still means reading every page, that's the number to fix first.
Where does your batch release lose the most time?
Biopharma sentiment hit 96 this quarter, up from 78 six months ago. The 12-month funding outlook dropped 13 points, back into negative territory. ⚠️
Translation: the money flowing right now might be the good part of the cycle, not the start. If your plan assumes this climate holds through next year, stress-test that now.
The full Q2 Biopharma Sentiment Index from Endpoints News: endpoints.news/biopharma-sen…
Geopolitics is now a first-order tech transfer driver. 🌍
BIOSECURE is law. WuXi AppTec landed on the DoD 1260H list in June 2026.
79% of surveyed companies have at least one Chinese-CDMO contract. That dependency runs through the whole industry.
Our 2026 read on tech transfer and supply resilience: a4bee.com/digital-cdmo/?utm_…
Enforcement is years out, with a five-year safe harbor. Treat that as planning runway, not a reprieve. Map your exposure and qualify alternates now.
Are you mapping yours?
Two companies were supposed to prove AI could discover drugs. Both are effectively gone. 💀 BenevolentAI's lead failed Phase 2a in 2023, cut ~a third of staff, shares fell 99%+ from a 1.5 billion euro SPAC. Exscientia wound down its lead, got absorbed by Recursion. Why?
The killer was concentration, not the science. One mid-stage failure is fatal when your whole story is one platform, one pipeline. Recursion then paused or killed five programs in May 2025. The Phase 2 wall doesn't care how fast you built the molecule. What survives it?
There's a second tech transfer almost nobody budgets for. 🔁
CDMO to CDMO, for commercial supply. An 18-24 month project, often between competitors.
The real risk is knowledge, not equipment. Lost tribal knowledge and gaps in the originating process can add a year-plus to a BLA.
How we help CDMOs capture and move process knowledge: a4bee.com/digital-cdmo/?utm_…